Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage [1]. Core Views - The company, Wuchan Zhongda Energy, is a state-owned enterprise in Zhejiang Province, transitioning from coal circulation to an integrated environmental energy service provider. It has a history dating back to 1950 and has expanded into the renewable energy sector since 2022 [4][14]. - The coal circulation business is stable, with the company leveraging its procurement advantages and technological capabilities to provide integrated services to suppliers and customers [36]. - The company operates six thermal power plants with a total installed capacity of 407 MW, focusing on stable demand in the Zhejiang region. It is also exploring waste disposal technologies [5][43]. - In the renewable energy sector, the company is advancing molten salt energy storage technology, which is expected to see significant growth in the coming years [49]. Summary by Sections Company Overview - Latest closing price: 12.77 CNY - Total shares: 5.58 billion - Total market capitalization: 71 billion CNY - Debt-to-asset ratio: 44.0% - Price-to-earnings ratio: 9.67 [3]. Business Segments - **Coal Circulation**: The primary revenue driver, accounting for 92.8% of revenue in 2024. The business is characterized by low margins but high turnover [26][36]. - **Thermal Power Generation**: The company has a stable demand in the Zhejiang region, with significant sales growth in steam and electricity [43][45]. - **Renewable Energy**: Focused on molten salt storage technology, with expected growth in installed capacity and investment [49]. Financial Forecasts - Projected revenues for 2025-2027 are 452.7 billion, 458.2 billion, and 463.6 billion CNY, respectively. Net profits are expected to be 7.9 billion, 8.5 billion, and 9.1 billion CNY, with a CAGR of 7.5% [6][57]. - The diluted EPS for the same period is forecasted at 1.42, 1.52, and 1.64 CNY [6][57]. Valuation and Rating - The company’s stock is expected to trade at PE multiples of 9, 8, and 8 times for the years 2025-2027, respectively. The report suggests a "Buy" rating based on the potential for further value expansion in thermal power assets [59].

证券研究报告：策略报告 大盘指数 7000 8000 9000 10000 11000 12000 2000 3000 4000 上证指数 深证成指 1000 2000 3000 5000 6000 7000 8000 中小100 创业板指 资料来源：聚源，中邮证券研究所 研究所 《以静待时》 - 2025.06.30 策略观点 关键节点将近，A 股或震荡消化涨幅 ⚫ 投资要点 本周 A 股继续拾级而上。本周主要股指除科创 50 外均有上涨， 其中沪深 300 上涨 1.54%表现最佳，其余主要指数本周涨幅较为接近， 中小市值个股居多的中证 500 和中证 1000 分别上涨 0.81%和 0.56%， 相对较弱。风格方面，本周所有风格指数均有上涨，金融风格上涨 1.86%最佳，成长风格较上周涨幅有明显回落。市值风格方面，本周大 中小盘市值风格均有上涨，大盘和中盘指数表现明显优于小盘指数。 本周代表核心资产和成长龙头的茅指数和宁组合亦有上涨，宁组合整 周上涨 2.23%，茅指数上涨 1.15%。 个人投资者情绪本周保持稳定。截至 7 月 5 日个人投资者情绪指 数 7 日移动平均数报 9.49%，较 6 月 ...

Industry Investment Rating - The industry investment rating is "Outperform" [2] Core Views - The report highlights that the PD-(L)1/VEGF bispecific antibody business development (BD) expectations are driving a sustained surge in the innovative drug market. AstraZeneca is in talks for a potential deal worth up to $15 billion with Summit Therapeutics for the PD-1/VEGF bispecific antibody AK112, indicating strong recognition from multinational corporations (MNCs) for this class of drugs [5][14] - The successful launch of Vuxin Qibai monoclonal antibody marks a harvest period for innovative drugs in the gout field, with the market for anti-gout drugs in China expected to grow from 2.2 billion yuan in 2024 to over 10 billion yuan by 2030 [6][32] - The pharmaceutical and biotechnology sector has seen a 3.64% increase, outperforming the CSI 300 index by 2.1 percentage points, ranking 4th among 31 sub-industries [7][41] Summary by Sections Weekly Insights - The report discusses the ongoing excitement in the innovative drug market driven by the PD-(L)1/VEGF bispecific antibody BD expectations and the successful market entry of Vuxin Qibai monoclonal antibody [5][6][14] Subsector Performance - The pharmaceutical and biotechnology sector rose by 3.64%, with other biopharmaceuticals showing the highest increase of 8.28%. The medical device sector experienced the largest decline at 0.21% [7][41][44] Recommended and Benefiting Stocks - Recommended stocks include: - Innovative drugs: Xinda Biopharma, Kangfang Biopharma, and others - Medical devices: Yingke Medical, Maipu Medical, and others - Benefiting stocks: Innovative drugs in H-shares and A-shares, including Zai Lab, Yifang Biopharma, and others [8][40][51]

Industry Investment Rating - The industry investment rating is "Outperform" and is maintained [2] Core Views - The report highlights the need to prevent disorderly competition and encourages companies to enhance product quality while promoting the orderly exit of outdated production capacity. Focus areas include silicon materials, coal chemical, and chlor-alkali chemical sectors, with price increases expected in potassium fertilizers, phosphorus fertilizers, active dyes, and pesticides [5][6] Summary by Sections Industry Overview - The closing index for the industry is at 3518.55, with a 52-week high of 3564.08 and a low of 2687.54 [2] - The basic chemical sector experienced a weekly change of +0.80%, underperforming the CSI 300 index, which had a weekly change of +1.54% [6][19] Stock Performance - Notable stock price increases include: - Kaimete Gas: +27.46% - Kete Biology: +21.90% - Jiuri New Materials: +21.01% [7][20] - Significant stock price decreases include: - Tiansheng New Materials: -15.80% - Jinji Co.: -15.34% - Xinyaqiang: -14.41% [8][21] Commodity Price Movements - Key commodities with price increases include: - Dichloropropane-white material: +8.82% - Isobutyraldehyde: +7.20% - TDI: +7.02% [9][23] - Key commodities with price decreases include: - Liquid chlorine: -86.51% - Chick seedlings: -47.31% - Meta-cresol: -9.09% [10][26] Investment Recommendations - The report suggests focusing on opportunities in silicon materials, coal chemical, and chlor-alkali chemical sectors while monitoring price trends in fertilizers and pesticides [5][6]

Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [2] Core Insights - The report highlights that the liquor sector is under pressure, with overall collection progress in Q2 lagging behind last year, and sales showing a year-on-year gap. The prices of major brands like Moutai and Wuliangye are under pressure due to regulatory measures aimed at reducing waste [5][15] - The beverage sector, particularly beer and dairy products, is expected to show varying performance, with some companies like Qingdao Beer and Yili maintaining growth while others face challenges [6][18] - The snack food segment is experiencing strong growth driven by channel optimization and product innovation, with companies like Youfu Foods and Yanjin Beer showing significant revenue increases [19][21] Summary by Sections 1. Liquor Sector - Q2 performance is expected to be weak for most liquor companies, with Moutai projected to have a revenue growth of 7% year-on-year, while Wuliangye is expected to decline by 2% [16] - Regulatory measures have impacted normal consumption scenarios, leading to a cautious approach from companies as they prepare for traditional consumption peaks during festivals [15] 2. Beer Sector - Qingdao Beer is expected to see slight growth due to low sales base in Q2 2024, while Chongqing Beer is projected to maintain sales levels [17] - Yanjin Beer is benefiting from supply chain management improvements, contributing to profitability [18] 3. Dairy Products - Yili is expected to face pressure in its ambient liquid milk segment, while other products like milk powder and ice cream continue to grow [18] - New Dairy is projected to maintain its performance in low-temperature categories, with profit growth expected to outpace revenue growth [18] 4. Soft Drinks - Eastroc Beverage is anticipated to continue its steady growth in energy drinks, while new products are expected to drive higher growth rates [19] - Chengde Lululemon is expected to see improvements in gross margins despite raw material price increases [19] 5. Snack Foods - Youfu Foods is focusing on channel optimization and product innovation, expecting significant revenue and profit growth [19] - Salted Fish and other snack companies are also projected to maintain strong growth, with new product launches expected to drive performance in the second half of the year [19][21] 6. Restaurant Supply Chain - Anji Foods is expected to achieve single-digit revenue growth, while competition continues to pressure margins [20] - Qianwei Central Kitchen is projected to maintain stable revenue, with slight pressure in the small B restaurant segment [20] 7. Export Companies - Zhongchong Co. is expected to maintain high revenue growth due to positive pre-sale feedback, while Xianle Health is projected to continue its growth trend despite some fluctuations in export business [21]

证券研究报告：机械设备|深度报告 发布时间：2025-07-07 行业投资评级 | 收盘点位 | | 1643.73 | | --- | --- | --- | | 52 | 周最高 | 1803.12 | | 52 | 周最低 | 1122.98 | 行业相对指数表现（相对值） -7% -1% 5% 11% 17% 23% 29% 35% 41% 47% 2024-07 2024-09 2024-11 2025-02 2025-04 2025-07 机械设备 沪深300 资料来源：聚源，中邮证券研究所 研究所 分析师:刘卓 SAC 登记编号:S1340522110001 Email:liuzhuo@cnpsec.com 分析师:傅昌鑫 SAC 登记编号:S1340524070004 Email:fuchangxin@cnpsec.com 近期研究报告 强于大市|维持 行业基本情况 《关注特斯拉 Optimus Gen3 发布》 - 2025.06.30 智元 G1、A2 等核心产品启动一定规模量产 ⚫ 本周行情回顾 本周（2025.06.30-07.04）人形机器人指数下跌-1.81%，跌幅超 过同期科创 ...

证券研究报告：固定收益报告 发布时间：2025-07-07 研究所 分析师:梁伟超 SAC 登记编号:S1340523070001 Email:liangweichao@cnpsec.com 近期研究报告 《超长期限暂时降温——信用周报 20250702》 - 2025.07.02 固收周报 策略选择"骑虎难下"？ ——流动性周报 20250706 ⚫ 持仓待涨，伺机止盈 资金利率下行突破政策利率，资金宽松到位。7 月上旬或是三季 度最宽松的时间窗口，后续资金面仍会存在季节波动，如 7 月中偏大 的税期和 7 月末至 8 月集中发行的政府债券等因素的影响仍在，但资 金面将整体保持稳定宽松态势，机构不宜过度揣测所谓政策意图来外 推资金面的变化，资金波动风险并不大。 同业存单利率下行至波动中枢，短端品种到位。从走廊角度看， 1 年国股行 NCD 利率的下限和上限在 1.4%-1.8%，中枢在 1.6%附近； 从交易角度看，1 年期国股行 NCD 利率在下半年的顶或在 1.7%，三季 度的底或在 1.55%附近。当前同业存单利率与资金移动中枢已经再次 回到小幅倒挂状态，同业存单利率下行基本到位。 公募仓位和久期升至 ...

Investment Rating - The report maintains a "Buy" rating for the company, expecting a significant increase in stock price relative to the benchmark index over the next six months [6][13]. Core Insights - The company is experiencing rapid growth in its self-owned brands, driven by both domestic and international business strategies. The positive feedback from the 618 pre-sale indicates strong growth potential for the brand "Wanpi" [4][5]. - The company has implemented a differentiated channel strategy, balancing online new business models with refined offline operations. The rise of direct sales and private domain operations is contributing to higher gross profit orders [5]. - The company's profitability is expected to improve due to product structure optimization and economies of scale, despite facing raw material price fluctuations [5]. Financial Projections - Revenue forecasts for 2025-2027 are set at 53.47 billion, 63.32 billion, and 74.43 billion yuan, reflecting year-on-year growth rates of 19.75%, 18.44%, and 17.54% respectively [6][9]. - The projected net profit attributable to the parent company for the same period is 4.7 billion, 5.95 billion, and 7.16 billion yuan, with growth rates of 19.46%, 26.40%, and 20.38% respectively [6][9]. - Earnings per share (EPS) are expected to be 1.55, 1.95, and 2.35 yuan for 2025, 2026, and 2027, corresponding to price-to-earnings (P/E) ratios of 40, 31, and 26 times [6][9].

Industry Investment Rating - The industry investment rating is "Outperform the Market" and is maintained [1]. Core Viewpoints - The nuclear medicine market is expected to grow significantly, with a projected global market size of USD 10.65 billion in 2023, reaching USD 31.44 billion by 2033, indicating a compound annual growth rate (CAGR) of 11.45% from 2024 to 2033 [4][19]. - The rise of Radionuclide Drug Conjugates (RDC) is a key driver for the nuclear medicine industry, with notable products like Pluvicto showing strong sales performance, achieving USD 1.392 billion in revenue in 2024, a 42% increase [19][22]. - China's nuclear medicine market is expected to grow from CNY 22 billion in 2017 to CNY 93 billion by 2025, with a CAGR of 32.4%, and further to CNY 260 billion by 2030, maintaining a high growth rate of 22.7% [26][28]. Summary by Sections Industry Overview - The closing index for the industry is 7754.01, with a 52-week high of 8490.25 and a low of 6070.89 [1]. Market Dynamics - The nuclear medicine sector is characterized by high barriers to entry and strong regulatory oversight, with significant advantages for companies with a comprehensive industry chain layout [6][29]. - The domestic nuclear medicine application level is significantly lower than that of developed countries, with a market primarily composed of traditional generic nuclear drugs [5][24]. Key Companies and Financial Projections - China Isotope & Radiation Corporation (1763.HK) and East China Pharmaceutical (002675.SZ) are leading players in the market, with extensive nuclear pharmacy networks and product pipelines [49][50]. - The financial performance of key companies indicates a robust growth trajectory, with China Isotope achieving a revenue of CNY 75.75 billion in 2024, and East China Pharmaceutical reporting CNY 10.12 billion in nuclear medicine revenue [49][50]. Regulatory Environment - Recent policies have been implemented to promote the development of the nuclear medicine industry, including the "Long-term Development Plan for Medical Isotopes (2021-2035)" which aims to enhance technology research and industry growth [26][27]. Future Outlook - The increasing focus on nuclear medicine, particularly in the context of precision therapy, is expected to drive further investment and innovation in the sector, with more domestic products anticipated to enter the market [19][24].

证券研究报告：宏观报告 研究所 分析师:李起 SAC 登记编号:S1340524110001 Email:liqi2@cnpsec.com 研究助理:高晓洁 SAC 登记编号:S1340124020001 Email:gaoxiaojie@cnpsec.com 近期研究报告 《内外利好共振，成长风格迎来布局窗 口》 - 2025.07.02 宏观观点 失业率意外下降，细节暗藏隐忧——6 月美国非农 数据解读 ⚫ 核心观点： 周四美国劳工部发布非农就业报告，6 月新增就业 14.7 万人，高 于预期的 11 万人，4、5 月合计上修 1.6 万人。6 月失业率小幅回落 至 4.1%，强于市场预期的 4.3%。在前一日公布的 ADP 就业数据疲软 后，这份亮眼的非农就业报告为美联储在 7 月维持利率不变提供了支 撑。然而，深入分析数据细节可以发现，失业率维持低位的背后，是 劳动力供需双双走弱的现实，这份报告仍然暗藏隐忧。 首先，劳动参与率有所下降，但按年龄划分，25-54 岁壮年群体 劳动参与率不降反升，年轻人的参与率下滑是主要拖累因素。其次， 美国平均每周工时和薪资增速均有所放缓，平均时薪环比仅增长 0.2%， ...